Case report: dynamics of acquired fluoroquinolone resistance under standardized short-course treatment of multidrug-resistant tuberculosis

Jean Claude Semuto Ngabonziza, Armand Van Deun, Patrick Migambi, Niyigena Esdras Belamo, Dusabe Théogène, Yves Mucyo Habimana, Bertin Ushizimpumu, Wim Mulders, Tom Decroo, Dissou Affolabi, Philip Supply, Bouke C de Jong, Leen Rigouts

Research output: Contribution to journalA1: Web of Science-article

Abstract

We report a case of acquired fluoroquinolone (FQ) resistance under short-course multidrug-resistant tuberculosis (MDR-TB) treatment. The patient was managed at Kabutare hospital, one of the two specialized MDR-TB clinics in Rwanda. A low dose of moxifloxacin was used in the first three critical months. Acquired resistance was identified at the ninth month of treatment, 3 months after stopping kanamycin in a strain initially susceptible only to FQs, kanamycin, and clofazimine. Fluoroquinolone resistance was detected in the same month by deep sequencing as routinely used second-line line probe assay and phenotypic drug susceptibility testing. High-dose FQ, preferably gatifloxacin, should be used to maximize effectiveness.

Original languageEnglish
JournalAmerican Journal of Tropical Medicine and Hygiene
Volume103
Issue number4
Pages (from-to)1443-1446
Number of pages4
ISSN0002-9637
DOIs
Publication statusPublished - 2020

Fingerprint

Dive into the research topics of 'Case report: dynamics of acquired fluoroquinolone resistance under standardized short-course treatment of multidrug-resistant tuberculosis'. Together they form a unique fingerprint.

Cite this